文献速递临床试验与 GCP基础与转化研究

褪黑素联合睡眠-觉醒行为安排在延迟睡眠-觉醒时相障碍中的随机双盲试验

Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial.
PubMed 文献 · PLoS Med · 2018-06-18

该随机双盲安慰剂对照试验在澳大利亚门诊延迟睡眠-觉醒时相障碍(DSWPD)患者中进行,比较0.5 mg速释褪黑素(就寝目标时间前1小时服用)联合睡眠-觉醒行为安排与安慰剂联合行为安排的疗效。结果显示褪黑素组入睡时间较安慰剂组提前34分钟(95%CI -8至-60),且主观睡眠相关损害、失眠严重度和功能残疾等指标改善更明显。

要点

  • 对褪黑素节律相对期望就寝时间延迟的DSWPD患者,0.5 mg褪黑素联合行为安排可提前入睡时间。
  • 褪黑素组临床医生评定的改善比例(52.8%)高于安慰剂组(24.0%),差异有统计学意义。
  • 治疗后褪黑素节律(DLMO)在组间无显著差异,长期疗效与安全性未评估。

核心结论

  • 在褪黑素节律相对期望就寝时间延迟的DSWPD患者中,就寝目标时间前1小时服用0.5 mg褪黑素联合睡眠-觉醒行为安排,可改善客观和主观睡眠指标。

研究设计与样本

  • 随机、安慰剂对照、双盲临床试验,在澳大利亚门诊DSWPD人群中进行,纳入褪黑素节律相对期望就寝时间延迟的患者。
  • 307例参与者注册,116例随机接受治疗(意向性分析n=116,男性62例,平均年龄29.0岁)。
  • 治疗为期4周,每周至少连续5晚于就寝目标时间前1小时服用0.5 mg速释褪黑素或安慰剂,所有患者均接受以就寝目标时间安排就寝的行为睡眠-觉醒安排。

主要发现

  • 与基线和安慰剂相比,褪黑素组入睡时间提前34分钟(95%CI -60至-8)。
  • 褪黑素组治疗夜前三分之一卧床时间的睡眠效率(SE T1)增加,PROMIS睡眠相关损害、PROMIS睡眠紊乱、失眠严重度和功能残疾均下降。
  • 褪黑素组临床医生评定改善超过最小改善的比例为52.8%,安慰剂组为24.0%(P<0.05)。
  • 两组按方案服药的夜数无差异;在部分患者(n=43)中评估的治疗后DLMO组间无显著差异。
  • 不良事件包括头昏、日间嗜睡和性欲下降,但两组发生率相似。

临床怎么用

  • 对于临床诊断DSWPD且内源性褪黑素节律相对期望就寝时间延迟的患者,可考虑就寝目标时间前1小时给予0.5 mg速释褪黑素并联合睡眠-觉醒行为安排。
  • 该治疗方案的长期疗效和安全性尚未评估,且不清楚相同方案是否适用于无内源性褪黑素节律延迟的DSWPD患者。

局限性

  • 未评估长期治疗的临床获益或安全性。
  • 尚不清楚相同治疗方案是否对无内源性褪黑素节律延迟的DSWPD患者有益。
  • 治疗后DLMO仅在部分患者(n=43)中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delayed Sleep-Wake Phase Disorder (DSWPD) is characterised by sleep initiation insomnia when attempting sleep at conventional times and difficulty waking at the required time for daytime commitments. Although there are published therapeutic guidelines for the administration of melatonin for DSWPD, to our knowledge, randomised controlled trials are lacking. This trial tested the efficacy of 0.5 mg melatonin, combined with behavioural sleep-wake scheduling, for improving sleep initiation in clinically diagnosed DSWPD patients with a delayed endogenous melatonin rhythm relative to patient-desired (or -required) bedtime (DBT). METHODS: This randomised, placebo-controlled, double-blind clinical trial was conducted in an Australian outpatient DSWPD population. Following 1-wk baseline, clinically diagnosed DSWPD patients with delayed melatonin rhythm relative to DBT (salivary dim light melatonin onset [DLMO] after or within 30 min before DBT) were randomised to 4-wk treatment with 0.5 mg fast-release melatonin or placebo 1 h before DBT for at least 5 consecutive nights per week. All patients received behavioural sleep-wake scheduling, consisting of bedtime scheduled at DBT. The primary outcome was actigraphic sleep onset time. Secondary outcomes were sleep efficiency in the first third of time in bed (SE T1) on treatment nights, subjective sleep-related daytime impairment (Patient Reported Outcomes Measurement Information System [PROMIS]), PROMIS sleep disturbance, measures of daytime sleepiness, clinician-rated change in illness severity, and DLMO time. FINDINGS: Between September 13, 2012 and September 1, 2014, 307 participants were registered; 116 were randomised to treatment (intention-to-treat n = 116; n = 62 males; mean age, 29.0 y). Relative to baseline and compared to placebo, sleep onset occurred 34 min earlier (95% confidence interval [CI] -60 to -8) in the melatonin group. SE T1 increased; PROMIS sleep-related impairment, PROMIS sleep disturbance, insomnia severity, and functional disability decreased; and a greater proportion of patients showed more than minimal clinician-rated improvement following melatonin treatment (52.8%) compared to placebo (24.0%) (P < 0.05). The groups did not differ in the number of nights treatment was taken per protocol. Post-treatment DLMO assessed in a subset of patients (n = 43) was not significantly different between groups. Adverse events included light-headedness, daytime sleepiness, and decreased libido, although rates were similar between treatment groups. The clinical benefits or safety of melatonin with long-term treatment were not assessed, and it remains unknown whether the same treatment regime would benefit patients experiencing DSWPD sleep symptomology without a delay in the endogenous melatonin rhythm. CONCLUSIONS: In this study, melatonin treatment 1 h prior to DBT combined with behavioural sleep-wake scheduling was efficacious for improving objective and subjective measures of sleep disturbances and sleep-related impairments in DSWPD patients with delayed circadian phase relative to DBT. Improvements were achieved largely through the sleep-promoting effects of melatonin, combined with behavioural sleep-wake scheduling. TRIAL REGISTRATION: This trial was registered with the Australian New Zealand Clinical Trials Registry, ACTRN12612000425897.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Sletten TL, Magee M, Murray JM, et al. Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial. PLoS Med. 2018. PMID: 29912983. doi:10.1371/journal.pmed.1002587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。